NYSEAMERICAN:PHGE BiomX (PHGE) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free PHGE Stock Alerts $0.35 -0.01 (-1.50%) (As of 05/10/2024 08:55 PM ET) Add Compare Share Share Today's Range$0.34▼$0.3850-Day Range N/A52-Week Range$0.19▼$0.86Volume39,400 shsAverage Volume1.88 million shsMarket Capitalization$19.58 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get BiomX alerts: Email Address BiomX MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside464.0% Upside$2.00 Price TargetShort InterestHealthy0.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.44 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiomX has only been the subject of 1 research reports in the past 90 days.Read more about BiomX's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.88% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently increased by 8.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHGE. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added BiomX to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.21% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BiomX are expected to grow in the coming year, from ($0.25) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About BiomX Stock (NYSEAMERICAN:PHGE)BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Read More PHGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHGE Stock News HeadlinesMay 3, 2024 | americanbankingnews.comBiomX (NYSEAMERICAN:PHGE) Stock Price Down 8.2%April 5, 2024 | seekingalpha.comBiomX Inc. (PHGE) Q4 2023 Earnings Call TranscriptMay 13, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 4, 2024 | msn.comBiomX Inc. (AMEX:PHGE) Q4 2023 Earnings Call TranscriptApril 4, 2024 | markets.businessinsider.comBiomX’s Robust Financial Health and Promising Clinical Advancements Bolster Buy RatingFebruary 14, 2024 | msn.comAzitra stock slides on pricing stock offering to raise $5 millionNovember 30, 2023 | finance.yahoo.comBiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023November 29, 2023 | benzinga.comWhy Is Bacterial Infection-Focused BiomX Stock Trading Lower Today?May 13, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.November 29, 2023 | msn.comBiomX mulls pivotal trial for antibacterial after Phase 1/2 data in cystic fibrosisNovember 29, 2023 | markets.businessinsider.comBiomX Announces Positive Results From Phase 1b/2a Study Of BX004 In Chronic Pulmonary InfectionsNovember 23, 2023 | seekingalpha.comBiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any DayNovember 16, 2023 | markets.businessinsider.comPromising Clinical Trials and Financial Stability Bolster BiomX’s Buy Rating: An Analysis by Michael HigginsNovember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BiomX (PHGE), Quoin Pharmaceuticals (QNRX) and Precigen (PGEN)October 27, 2023 | finance.yahoo.comBiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis ConferenceOctober 18, 2023 | finance.yahoo.comBiomX Announces the Appointment of Edward L. Williams to its Board of DirectorsOctober 4, 2023 | finance.yahoo.comBiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic FibrosisSeptember 7, 2023 | finance.yahoo.comBiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023September 6, 2023 | finance.yahoo.comBiomX to Present at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 9, 2023 | finance.yahoo.comBiomX Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comBiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023June 8, 2023 | finance.yahoo.comNYSE American Initiates Delisting Proceedings for BiomX WarrantsMay 15, 2023 | finance.yahoo.comBiomX Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 12, 2023 | finance.yahoo.comBiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of DirectorsMay 5, 2023 | finance.yahoo.comBiomX Announces Second Closing of $7.5 Million Private PlacementMarch 27, 2023 | finance.yahoo.comBiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023February 24, 2023 | msn.comWhy Is BiomX (PHGE) Stock Down 18% Today?See More Headlines Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2024Today5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:PHGE CUSIPN/A CIKN/A Webwww.biomx.com Phone972-7-2394-2377FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+464.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-242.05% Return on Assets-74.37% Debt Debt-to-Equity Ratio1.75 Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book5.07Miscellaneous Outstanding Shares55,220,000Free Float52,895,000Market Cap$19.58 million OptionableN/A Beta1.31 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jonathan Eitan Solomon MBA (Age 47)CEO & Director Comp: $528.57kMs. Marina Wolfson CPA (Age 40)CFO & Secretary Comp: $279.42kDr. Merav Bassan Ph.D. (Age 58)Chief Development Officer Comp: $356.59kProf. Rotem Sorek Ph.D.Scientific FounderDr. Eran Elinav M.D.Ph.D., Scientific FounderDr. Timothy K. Lu M.D. (Age 43)Ph.D., Scientific Founder Ms. Inbal Benjamini-ElranC.H.R.OMr. Assaf Oron (Age 50)Chief Business Officer Comp: $352.04kMore ExecutivesKey CompetitorsZIVO BioscienceNASDAQ:ZIVOAIM ImmunoTechNYSE:AIMEvaxion Biotech A/SNASDAQ:EVAXBrainstorm Cell TherapeuticsNASDAQ:BCLIAptose BiosciencesNASDAQ:APTOView All CompetitorsInsidersAssaf OronSold 10,914 sharesTotal: $4,038.18 ($0.37/share) PHGE Stock Analysis - Frequently Asked Questions Should I buy or sell BiomX stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PHGE shares. View PHGE analyst ratings or view top-rated stocks. What is BiomX's stock price target for 2024? 1 Wall Street research analysts have issued 12 month price objectives for BiomX's shares. Their PHGE share price targets range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next year. This suggests a possible upside of 464.0% from the stock's current price. View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts. Are investors shorting BiomX? BiomX saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 155,100 shares, a decrease of 28.9% from the March 31st total of 218,100 shares. Based on an average trading volume of 2,540,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.8% of the company's shares are short sold. View BiomX's Short Interest. How were BiomX's earnings last quarter? BiomX Inc. (NYSEAMERICAN:PHGE) announced its quarterly earnings results on Wednesday, April, 3rd. The company reported ($0.08) earnings per share for the quarter. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:PHGE) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorBill Clinton Backing Biden Replacement???The Freeport SocietyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
